Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Emerging pharmacological treatment options for MAFLD

  • Rojas, Ángela
  • Lara-Romero, Carmen
  • Muñoz-Hernández, Rocío
  • Gato, Sheila
  • Ampuero, Javier
  • Romero-Gómez, Manuel
Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension, hypertriglyceridemia, hypercholesterolemia, insulin resistance, and cardiovascular risk, increasing the risk of mortality. The excessive accumulation of fat comprises apoptosis, necrosis, inflammation and ballooning degeneration progressing to fibrosis, cirrhosis, and liver decompensations including hepatocellular carcinoma development. The limitation of approved drugs to prevent MAFLD progression is a paradigm. This review focuses on recent pathways and targets with evidence results in phase II/III clinical trials., Ministerio de Ciencia y Competitividad under grant agreements PI19/01404 and PI19/00589. A contract with fellowship from Consejería de Salud y Familias, Junta de Andalucía, supporting Angela Rojas (RH-002-2021); grant agreements PFIS FI20/00201 from Instituto de Salud Carlos III to support Sheila Gato and by support from Talento Doctores (PID Junta Andalucía, DOC_00866) to Rocío Muñoz-Hernández., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies

  • Rojas, Ángela
  • García-Lozano, María del Rosario
  • Gil-Gómez, Antonio
  • Romero-Gómez, Manuel
  • Ampuero, Javier
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, reflecting the current epidemics of obesity, insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. NAFLD is characterized by the accumulation of fat in the liver, and is known to be a cause of cirrhosis. Although many pathways have been proposed, the cause of NAFLD-linked fibrosis progression is still unclear, which posed challenges for the development of new therapies to prevent NASH-related cirrhosis and hepatocellular carcinoma. Cirrhosis is associated with activation of hepatic stellate cells (HSC) and accumulation of excess extracellular matrix proteins, and inhibiting the activation of HSCs would be expected to slow the progression of NAFLD-cirrhosis. Multiple molecular signals and pathways such as oxidative stress and glutaminolysis have been reported to promote HSC activation. Both mechanisms are plausible antifibrotic targets in NASH, as the activation of HSCs the proliferation of myofibroblasts depend on those processes. This review summarizes the role of the glutaminolysis-ammonia-urea cycle axis in the context of NAFLD progression, and shows how the axis could be a novel therapeutic target., This project was funded in part by the Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III (PI19/00589, PI19/01404, PI16/01842, PI17/00535 and GLD19/00100). Ángela Rojas has received the Sara Borrell postdoctoral fellowships from Instituto de Salud Carlos III CD18/00126 to support her postdoctoral contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD

  • Ampuero, Javier
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Montero, Rocío
  • Gato, Sheila
  • Rojas, Ángela
  • Gil, Antonio
  • Muñoz, Rocío
  • Romero-Gómez, Manuel
[Background] NAFLD clinical trials have shown suboptimal results, particularly for liver fibrosis, despite the robust preclinical drug development. We aimed to assess the histological response after the experimental treatment versus placebo by carrying out a meta-analysis of NAFLD clinical trials., [Methods] After a systematic review of NAFLD clinical trials to May 2021, applying strict selection criteria, the following primary outcomes were observed: (a) NASH resolution, with no worsening of fibrosis when available; (b) fibrosis improvement  ≥ 1 stage, with no worsening of NAS when available; (c) worsening of NAS; (d) worsening of liver fibrosis  ≥ 1 stage, including the progression to cirrhosis on histopathology. Other histological, clinical, and biochemical outcomes were considered secondary endpoints. Heterogeneity was explored by subgroup and sensitivity analyses, and univariable meta-regression., [Results] Twenty-seven randomized clinical trials were included. The pooled efficacy for NASH resolution receiving experimental therapy was 19% (95%CI 15–23; I2 96.2%) compared with placebo 10% (95%CI 7–12; I2 85.8%) (OR 1.66 (95%CI 1.24–2.21); I2 57.8%), while it was 26% (95%CI 22–29); I2 90%)) versus 18% (95%CI 15–21; I2 59%)) for fibrosis improvement (OR 1.34 (95%CI 1.13–1.58); I2 25.4%). For these outcomes, the therapy showed higher efficacy in trials longer than 48 weeks, with  < 60% of diabetic population, and when it targeted FXR, PPAR, and antidiabetic mechanisms, and with a NAS  < 5 for NASH resolution. Also, NASH (OR 0.57 (95%CI 0.39–0.84); I2 67%) and fibrosis worsening (OR 0.65 (95%CI 0.46–0.92); I2 61.9%) were prevented with the therapy., [Conclusion] This meta-analysis provides information about the efficacy of the therapy versus placebo by comparing different and combined trial outcomes such as NASH resolution, fibrosis improvement, and NAS and fibrosis worsening. Changes in the experimental design and selection criteria of the clinical trials might be suitable to increase the efficacy., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This project has been partially funded by the “Consejería de Salud de la Junta de Andalucía” (PI-0075–2014), the “Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III” (PI16/01842, PI17/00535, PI19/01404, PI19/00589, IFI18/00041 and GLD19/00100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses

  • García-Lozano, María del Rosario
  • Dragoni, Filippo
  • Gallego, Paloma
  • Mazzotta, Sarah
  • López-Gómez, Alejandro
  • Boccuto, Adele
  • Martínez-Cortés, Carlos
  • Rodríguez-Martínez, Alejandro
  • Pérez-Sánchez, Horacio
  • Vega-Pérez, José Manuel
  • Campo, José A. del
  • Vicenti, Ilaria
  • Vega-Holm, Margarita
  • Iglesias-Guerra, Fernando
© 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., Since 2011 Direct Acting antivirals (DAAs) drugs targeting different non-structural (NS) viral proteins (NS3, NS5A or NS5B inhibitors) have been approved for clinical use in HCV therapies. However, currently there are not licensed therapeutics to treat Flavivirus infections and the only licensed DENV vaccine, Dengvaxia, is restricted to patients with preexisting DENV immunity. Similarly to NS5 polymerase, the NS3 catalytic region is evolutionarily conserved among the Flaviviridae family sharing strong structural similarity with other proteases belonging to this family and therefore is an attractive target for the development of pan-flavivirus therapeutics. In this work we present a library of 34 piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. The library was developed through a privileged structures-based design and then biologically screened using a live virus phenotypic assay to determine the half-maximal inhibitor concentration (IC50) of each compound against ZIKV and DENV. Two lead compounds, 42 and 44, with promising broad-spectrum activity against ZIKV (IC50 6.6 µM and 1.9 µM respectively) and DENV (IC50 6.7 µM and 1.4 µM respectively) and a good security profile were identified. Besides, molecular docking calculations were performed to provide insights about key interactions with residues in NS3 proteases’ active sites., This work has been supported by Ministerio de Ciencia, Innovación y Universidades, Plan Estatal 2017-2020 Retos - Proyectos I + D + i (PID2019-104767RB-I00). MRGL also thanks Ministerio de Economía y Competitividad, Instituto de Salud Carlos III (grants PI19/00589, PI19/01404, PI16/01842, PI17/00535 and GLD19/00100) for financial support., This work was supported by funds from MIUR Ministero dell’Istruzione, dell’Università della Ricerca Italiano, project PRIN 2017, ORIGINALE CHEMIAE in Antiviral Strategy—Origin and Modernization of Multi-Component Chemistry as a Source of Innovative Broad-Spectrum Antiviral Strategy (cod. 2017BMK8JR) and from Tuscany region, project Tuscany Antiviral Research Network -TUSCAVIR.NET (Bando Ricerca Salute 2018). We would like to thank Giulietta Venturi for making the ZIKV H/PF/2013 strain available for this study., This work has also been funded by the Fundación Séneca de la Región de Murcia under Project 20988/PI/18., This research was partially supported by the computer resources and the technical support provided by the supercomputing infrastructure of the NLHPC (ECM-02), Powered@NLHPC and the Extremadura Research Centre for Advanced Technologies (CETA − CIEMAT), funded by the European Regional Development Fund (ERDF). CETA − CIEMAT is part of CIEMAT and the Government of Spain., Authors thank CITIUS (Centro de Investigación, Tecnología e Innovación de la Universidad de Sevilla) for its important contribution in recording NMR and Mass spectra and in elemental analysis determination., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells

  • Guillén-Mancina, Emilio
  • García-Lozano, María del Rosario
  • Burgos-Morón, Estefanía
  • Mazzotta, Sarah
  • Martínez-Aguado, Pablo
  • Calderón-Montaño, José Manuel
  • Vega-Pérez, José Manuel
  • López-Lázaro, Miguel
  • Iglesias-Guerra, Fernando
  • Vega-Holm, Margarita
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Breast cancer is the most common type of cancer in women. Although current treatments can increase patient survival, they are rarely curative when the disease is advanced (metastasis). Therefore, there is an urgent need to develop new cytotoxic drugs with a high selectivity toward cancer cells. Since repurposing approved drugs for cancer therapy has been a successful strategy in recent years, in this study, we screened a library of antiviral piperazine-derived compounds as anticancer agents. The compounds included a piperazine ring and aryl urea functions, which are privileged structures present in several anti-breast cancer drugs. The selective cytotoxic activity of a set of thirty-four 4-acyl-2-substituted piperazine urea derivatives against MCF7 breast cancer cells and MCF 10A normal breast cells was determined. Compounds 31, 32, 35, and 37 showed high selective anticancer activity against breast cancer cells and were also tested against another common type of cancer, non-small cell lung cancer (A549 lung cancer cells versus MRC-5 lung normal cells). Compounds 35 and 37 also showed selectivity against lung cancer cells. These results suggest that compounds 35 and 37 may be promising hit compounds for the development of new anticancer agents., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Plan Estatal 2017-2020 Retos-Proyectos I + D + i (PID2019-104767RB-I00). M.d.R.G.-L. also thanks Ministerio de Economía y Competitividad, Instituto de Salud Carlos III (grants PI19/00589, PI19/01404, PI16/01842, PI17/00535, and GLD19/00100) for financial support. Additional support was given by Junta de Andalucía (grant numbers 2017/CTS-657 and 2019/CTS-657) and the University of Seville through the “V Plan Propio de Investigación y Transferencia” (grant number PPI2015-II.2), the “VI Plan Propio de Investigación y Transferencia” (grant numbers VIPPIT-2019-I.5 and VIPPIT-2020-I.5) and the “VII Plan Propio de Investigación y Transferencia” (grant number VIIPPIT-2023-I.3)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD

  • Muñoz-Hernández, Rocío
  • Gato, Sheila
  • Gil-Gómez, Antonio
  • Aller, Rocío
  • Rojas, Ángela
  • Morán, Laura
  • Gallego, Javier
  • Blázquez-López, Elena
  • Gallego-Durán, Rocío
  • Montero-Vallejo, Rocío
  • García-Fernández, Vanessa
  • Maya-Miles, Douglas
  • Rico, María Carmen
  • Cubero, Francisco Javier
  • Vaquero, Javier
  • Ampuero, Javier
  • Bañares, Rafael
  • Romero-Gómez, Manuel
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Background and Aims] Extracellular vesicles (EVs) have emerged as a potential source of circulating biomarkers in liver disease. We evaluated circulating AV+ EpCAM+ CD133+ EVs as a potential biomarker of the transition from simple steatosis to steatohepatitis., [Methods] EpCAM and CD133 liver proteins and EpCAM+ CD133+ EVs levels were analysed in 31 C57BL/6J mice fed with a chow or high fat, high cholesterol and carbohydrates diet (HFHCC) for 52 weeks. The hepatic origin of MVs was addressed using AlbCrexmT/mG mice fed a Western (WD) or Dual diet for 23 weeks. Besides, we assessed plasma MVs in 130 biopsy-proven NAFLD patients., [Results] Hepatic expression of EpCAM and CD133 and EpCAM+ CD133+ EVs increased during disease progression in HFHCC mice. GFP+ MVs were higher in AlbCrexmT/mG mice fed a WD (5.2% vs 12.1%) or a Dual diet (0.5% vs 7.3%). Most GFP+ MVs were also positive for EpCAM and CD133 (98.3% and 92.9% respectively), suggesting their hepatic origin. In 71 biopsy-proven NAFLD patients, EpCAM+ CD133+ EVs were significantly higher in those with steatohepatitis compare to those with simple steatosis (286.4 ± 61.9 vs 758.4 ± 82.3; p < 0.001). Patients with ballooning 367 ± 40.6 vs 532.0 ± 45.1; p = 0.01 and lobular inflammation (321.1 ± 74.1 vs 721.4 ± 80.1; p = 0.001), showed higher levels of these EVs. These findings were replicated in an independent cohort., [Conclusions] Circulating levels of EpCAM+ CD133+ MVs in clinical and experimental NAFLD were increased in the presence of steatohepatitis, showing high potential as a non-invasive biomarker for the evaluation and management of these patients., This work was supported by Consejería de Salud y Familias (PI-0039-2017 to RM), Sociedad Andaluza de Patología Digestiva (Beca Dr. Gonzalo Miño Fugarolas to RM), Talento Doctores (PID Junta Andalucía, DOC_00866, to RM), Consejería Economía, Conocimiento, Empresas y Universidad, Proyecto P20_01075 de financiación pública en la convocatoria 2020 en la modalidad Ayudas a proyectos de I+D+i, destinadas a las universidades y entidades públicas de investigación calificadas como agentes del Sistema Andaluz del Conocimiento, en el ámbito del Plan Andaluz de Investigación, Desarrollo e Innovación (PAIDI 2020). Convocatoria financiada con Fondo Europeo de Desarrollo Regional (FEDER) al 80%. Andalucía se mueve con Europa to MR. Instituto de Salud Carlos III to MR/RM (PI19/00589), to MR (PMP21/00078) and PI22/01342 to MR, PFIS FI20/00201 to SG, Consejería de Salud y Familias, Junta de Andalucía to AGG (RH-122-2020) and AR (RH-002-2021), i-PFIS 18/00041 to RM, Sara Borrel CD21-00095 to RGD and Comunidad de Madrid y Fondos FEDER ‘Una manera de hacer Europa’, S2017/BMD3727, ExoHep-CM to RB., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel insights into metabolic-associated steatotic liver disease preclinical models

  • Montero-Vallejo, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Martín, Franz
  • Romero-Gómez, Manuel
  • Gallego-Durán, Rocío
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims., The research leading to these results has received funding from the Consejería de Salud de la Junta de Andalucía under grant agreement PC-0148-2016-0148 and PE-0451-2018, and from the Instituto de Salud Carlos III under grant agreements CD21/00095, PI19/01404, PI19/00589, PI22/01342, PI22/01345 and IFI18/00041 and Ministerio de Economía y Competitividad under grant agreement AGL-2017-86927-R and PID2020-116731RB-C21. Rocío Montero-Vallejo has received the Juan Manuel Herrerías from Sociedad Andaluza de Patología Digestiva, CIBERehd grants to support mobility and improve mice handling. Rocío Gallego-Durán has received the Andrew K Burroughs Fellowship from European Association for the Study of the Liver (EASL), Aprendizaje de Nuevas Tecnologías fellowship from Asociación Española para el Estudio del Hígado (AEEH) and CIBERehd Grant to support researcher's mobility., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detailed stratified GWAS analysis for severe COVID-19 in four European populations

  • Degenhardt, Frauke|||0000-0001-7516-3179
  • Ellinghaus, David|||0000-0002-4332-6110
  • Juzenas, Simonas
  • Lerga Jaso, Jon|||0000-0003-4807-1900
  • Wendorff, Mareike
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Uellendahl-Werth, Florian
  • ElAbd, Hesham
  • Rühlemann, Malte C.
  • Arora, Jatin
  • Özer, Onur
  • Lenning, Ole Bernt
  • Myhre, Ronny
  • Vadla, May Sissel
  • Wacker, Eike M.
  • Wienbrandt, Lars|||0000-0001-5685-2032
  • Blandino Ortiz, Aaron|||0000-0002-3184-6418
  • de Salazar, Adolfo|||0000-0002-4318-858X
  • Garrido Chercoles, Adolfo
  • Palom, Adriana|||0000-0002-0130-1302
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Garcia-Fernandez, Alba-Estela|||0000-0003-4957-0373
  • Blanco-Grau, Albert|||0000-0002-4213-3827
  • Mantovani, Alberto
  • Zanella, Alberto
  • Holten, Aleksander Rygh
  • Mayer, Alena
  • Bandera, Alessandra
  • Cherubini, Alessandro
  • Protti, Alessandro|||0000-0002-0172-6079
  • Aghemo, Alessio
  • Gerussi, Alessio
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Braun, Alice|||0000-0003-1145-0261
  • Nebel, Almut
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Lleo, Ana
  • Teles, Ana
  • Kildal, Anders Benjamin|||0000-0002-1319-6511
  • Biondi, Andrea
  • Caballero, Andrea|||0000-0003-2891-6347
  • Ganna, Andrea|||0000-0002-8147-240X
  • Gori, Andrea|||0000-0001-6587-4794
  • Glück, Andreas
  • Lind, Andreas
  • Tanck, Anja
  • Hinney, Anke|||0000-0001-5659-0706
  • Carreras Nolla, Anna|||0000-0002-8789-067X
  • Fracanzani, Anna Ludovica
  • Peschuck, Anna
  • Cavallero, Annalisa
  • Dyrhol-Riise, Anne Ma
  • Ruello, Antonella
  • Julià Cano, Antonio|||0000-0001-6064-3620
  • Muscatello, Antonio
  • Pesenti, Antonio|||0000-0003-2593-729X
  • Voza, Antonio
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Solier, Aurora
  • Schmidt, Axel|||0000-0002-9780-7243
  • Cortés, Beatriz|||0000-0002-2656-7051
  • Mateos Muñoz, Beatriz|||0000-0003-0326-4119
  • Nafria-Jimenez, Beatriz|||0000-0002-4698-5680
  • Schaefer, Benedikt
  • Jensen, Björn
  • Bellinghausen, Carla
  • Maj, Carlo
  • Ferrando, Carlos|||0000-0002-1907-5323
  • de la Horra, Carmen
  • Quereda, Carmen
  • Skurk, Carsten
  • Thibeault, Charlotte
  • Scollo, Chiara
  • Herr, Christian
  • Spinner, Christoph D.|||0000-0002-3875-5367
  • Gassner, Christoph
  • Lange, Christoph|||0000-0002-9691-4741
  • Hu, Cinzia
  • Paccapelo, Cinzia
  • Lehmann, Clara
  • Angelini, Claudio
  • Cappadona, Claudio
  • Azuure, Clinton
  • Bianco, Cristiana
  • Cea López, Cristina|||0000-0003-0776-6706
  • Sancho, Cristina
  • Hoff, Dag Arne Lihaug
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Prati, Daniele|||0000-0002-2281-7498
  • Haschka, David
  • Jiménez, David|||0000-0002-4571-7721
  • Pestaña, David
  • Toapanta, David
  • Muñíz Díaz, Eduardo
  • Azzolini, Elena
  • Sandoval, Elena|||0000-0002-4242-5133
  • Binatti, Eleonora
  • Scarpini, Elio|||0000-0002-6395-2119
  • Helbig, Elisa T.
  • Casalone, Elisabetta
  • Urrechaga, Eloisa
  • Paraboschi, Elvezia Maria|||0000-0002-7935-798X
  • Pontali, Emanuele|||0000-0002-1085-0442
  • Reverter, Enric|||0000-0002-4967-6947
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Navas, Enrique|||0000-0001-9561-1338
  • Solligård, Erik
  • Contro, Ernesto
  • Arana-Arri, Eunate|||0000-0001-9759-333X
  • Aziz, Fátima
  • Garcia, Federico
  • García Sánchez, Félix|||0000-0002-6965-5940
  • Ceriotti, Ferruccio|||0000-0002-0958-5354
  • Martinelli-Boneschi, Filippo
  • Peyvandi, Flora|||0000-0001-7423-9864
  • Kurth, Florian
  • Blasi, Francesco|||0000-0002-2285-9970
  • Malvestiti, Francesco
  • Medrano, Francisco J.
  • Mesonero, Francisco|||0000-0002-7864-8187
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Hanses, Frank
  • Müller, Fredrik
  • Hemmrich-Stanisak, Georg
  • Bellani, Giacomo
  • Grasselli, Giacomo|||0000-0002-1735-1400
  • Pezzoli, Gianni
  • Costantino, Giorgio
  • Albano, Giovanni
  • Cardamone, Giulia
  • Bellelli, Giuseppe
  • Citerio, Giuseppe|||0000-0002-5374-3161
  • Foti, Giuseppe
  • Lamorte, Giuseppe
  • Matullo, Giuseppe
  • Baselli, Guido
  • Kurihara, Hayato
  • Neb, Holger
  • My, Ilaria
  • Kurth, Ingo|||0000-0002-5642-8378
  • Hernández, Isabel|||0000-0001-8119-393X
  • Pink, Isabell
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Galván-Femenía, Iván|||0000-0002-6124-3730
  • Holter, Jan Cato
  • Afset, Jan Egil
  • Heyckendorf, Jan|||0000-0003-4203-8421
  • Kässens, Jan
  • Damås, Jan Kristian
  • Rybniker, Jan
  • Altmüller, Janine|||0000-0003-4372-1521
  • Ampuero, Javier|||0000-0002-8332-2122
  • Martín, Javier|||0000-0002-2202-0622
  • Erdmann, Jeanette|||0000-0002-4486-6231
  • Banales, Jesus|||0000-0002-5224-2373
  • Badia, Joan Ramon
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Schneider, Jochen
  • Bergan, Jonas|||0000-0003-4267-8904
  • Barretina, Jordi|||0000-0002-3478-4080
  • Walter, Jörn
  • Hernández Quero, José
  • Goikoetxea, Josune
  • Delgado Cuesta, Juan|||0000-0002-5947-6287
  • Guerrero, Juan M.
  • Fazaal, Julia
  • Kraft, Julia|||0000-0001-7306-1179
  • Schröder, Julia
  • Risnes, Kari
  • Banasik, Karina|||0000-0003-2489-2499
  • Müller, Karl Erik
  • Gaede, Karoline I.
  • Garcia-Etxebarria, Koldo
  • Tonby, Kristian
  • Heggelund, Lars
  • Izquierdo-Sanchez, Laura
  • Bettini, Laura Rachele|||0000-0002-0280-1704
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Sander, Leif Erik
  • Lippert, Lena J.
  • Terranova, Leonardo
  • Nkambule, Lindokuhle
  • Knopp, Lisa
  • Gustad, Lise Tuset
  • Garbarino, Lucia
  • Santoro, Luigi
  • Téllez, Luis|||0000-0002-9254-3891
  • Roade, Luisa|||0000-0002-8160-9613
  • Ostadreza, Mahnoosh
  • Intxausti, Maider
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Berger, Marc M.
  • Schaefer, Marco
  • Niemi, Mari E. K.
  • Gutiérrez-Stampa, María Ángeles
  • Carrabba, Maria
  • Figuera Basso, Maria E.
  • Valsecchi, Maria Grazia
  • Hernández Tejero, María|||0000-0002-6782-9150
  • Vehreschild, Maria J. G. T.
  • Manunta, Maria|||0000-0002-1875-5335
  • Acosta-Herrera, Marialbert|||0000-0002-9868-6535
  • D'Angio, Mariella|||0000-0001-7889-8576
  • Baldini, Marina
  • Cazzaniga, Marina Elena|||0000-0003-1756-6935
  • Grimsrud, Marit M.
  • Cornberg, Markus|||0000-0002-9141-8001
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Marquié, Marta|||0000-0002-0660-0950
  • Castoldi, Massimo
  • Cordioli, Mattia|||0000-0002-4872-0520
  • Cecconi, Maurizio|||0000-0002-4376-6538
  • D'Amato, Mauro
  • Augustin, Max|||0000-0002-2300-9337
  • Tomasi, Melissa
  • Boada, Mercè|||0000-0003-2617-3009
  • Dreher, Michael
  • Seilmaier, Michael J.
  • Joannidis, Michael
  • Wittig, Michael
  • Mazzocco, Michela
  • Ciccarelli, Michele|||0000-0003-2379-1960
  • Rodríguez-Gandía, Miguel
  • Bocciolone, Monica
  • Miozzo, Monica
  • Imaz Ayo, Natale|||0000-0001-9087-901X
  • Blay, Natalia|||0000-0002-7160-8529
  • Chueca, Natalia|||0000-0002-3420-3290
  • Montano, Nicola
  • Braun, Nicole
  • Ludwig, Nicole|||0000-0003-4703-7567
  • Marx, Nikolaus
  • Martínez, Nilda
  • Cornely, Oliver A.|||0000-0001-9599-3137
  • Witzke, Oliver
  • Palmieri, Orazio
  • Faverio, Paola|||0000-0002-0360-1237
  • Preatoni, Paoletta
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Omodei, Paolo
  • Tentorio, Paolo
  • Castro Rebollo, Pedro|||0000-0002-6118-8970
  • Rodrigues, Pedro M.
  • España, PP.|||0000-0001-5723-8253
  • Hoffmann, Per|||0000-0002-6573-983X
  • Rosenstiel, Philip|||0000-0002-9692-8828
  • Schommers, Philipp
  • Suwalski, Phillip
  • de Pablo, Raúl
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Bals, Robert
  • Gualtierotti, Roberta
  • Gallego-Durán, Rocío
  • Nieto, Rosa
  • Carpani, Rossana
  • Morilla, Rubén
  • Badalamenti, Salvatore
  • Haider, Sammra
  • Ciesek, Sandra
  • May, Sandra
  • Bombace, Sara
  • Marsal, Sara|||0000-0001-5515-3854
  • Pigazzini, Sara
  • Klein, Sebastian
  • Pelusi, Serena
  • Wilfling, Sibylle
  • Bosari, Silvano
  • Volland, Sonja
  • Brunak, Søren|||0000-0003-0316-5866
  • Raychaudhuri, Soumya|||0000-0002-1901-8265
  • Schreiber, Stefan
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Aliberti, Stefano|||0000-0002-0090-4531
  • Ripke, Stephan|||0000-0003-3622-835X
  • Dudman, Susanne|||0000-0001-5047-4982
  • Wesse, Tanja
  • Zheng, Tenghao
  • Bahmer, Thomas
  • Eggermann, Thomas
  • Illig, Thomas
  • Brenner, Thorsten
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Feldt, Torsten
  • Folseraas, Trine
  • Gonzalez Cejudo, Trinidad
  • Landmesser, Ulf
  • Protzer, Ulrike|||0000-0002-9421-1911
  • Hehr, Ute
  • Rimoldi, Valeria
  • Monzani, Valter
  • Skogen, Vegard
  • Keitel, Verena
  • Kopfnagel, Verena
  • Friaza, Vicente|||0000-0002-2900-4334
  • Andrade, Victor|||0000-0003-0682-269X
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Morros, Rosa|||0000-0001-6752-8748
  • Albrecht, Wolfgang
  • Peter, Wolfgang
  • Poller, Wolfgang
  • Farré Ramon, Xavier|||0000-0001-6838-9479
  • Yi, Xiaoli
  • Wang, Xiaomin
  • Khodamoradi, Yascha|||0000-0001-5972-0967
  • Karadeniz, Zehra
  • Latiano, Anna
  • Goerg, Siegfried
  • Bacher, Petra
  • Koehler, Philipp|||0000-0002-7386-7495
  • Tran, Florian
  • Zoller, Heinz|||0000-0003-1794-422X
  • Schulte, Eva C.|||0000-0003-3105-5672
  • Heidecker, Bettina
  • Ludwig, Kerstin U.|||0000-0002-8541-2519
  • Fernández, Javier|||0000-0002-5622-0489
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Albillos, Agustín|||0000-0001-9131-2592
  • Invernizzi, Pietro|||0000-0003-3262-1998
  • Buti, Maria|||0000-0002-0732-3078
  • Duga, Stefano
  • Bujanda, Luis|||0000-0002-4353-9968
  • Hov, Johannes R.|||0000-0002-5900-8096
  • Lenz, Tobias L.
  • Asselta, Rosanna
  • de Cid, Rafael|||0000-0003-3579-6777
  • Valenti, Luca|||0000-0001-8909-0345
  • Karlsen, Tom H.
  • Cáceres Aguilar, Mario|||0000-0002-7736-3251
  • Franke, Andre|||0000-0003-1530-5811
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended genome-wide association meta-analysis of a well-characterized cohort of 3255 COVID-19 patients with respiratory failure and 12 488 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a ~0.9-Mb inversion polymorphism that creates two highly differentiated haplotypes and characterized the potential effects of the inversion in detail. Our data, together with the 5th release of summary statistics from the COVID-19 Host Genetics Initiative including non-Caucasian individuals, also identified a new locus at 19q13.33, including NAPSA, a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients

  • Gil-Gómez, Antonio
  • Rojas, Ángela|||0000-0003-0853-4800
  • García-Lozano, María R.
  • Muñoz-Hernández, Rocío
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Montero-Vallejo, Rocío
  • Gato, Sheila
  • Gallego, Javier
  • Francés, Rubén
  • Soriano, German|||0000-0002-9267-6811
  • Ampuero, Javier|||0000-0002-8332-2122
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced fibrosis and cirrhosis. In this study, we aimed to evaluate the prognosis of cirrhotic patients harboring this variant. We performed a retrospective analysis on 483 prospectively recruited patients from four different hospitals in Spain, followed-up for at least 5 years. We collected clinical, demographic, and biochemical data, and we performed a genotyping analysis for common variants previously associated with liver disease risk (HSD17B13 rs72613567:TA and PNPLA3 rs738409). Patients homozygous for the TA allele showed a higher MELD score (p = 0.047), Child-Turcotte-Pugh score (p = 0.014), and INR levels (p = 0.046), as well as decreased albumin (p = 0.004) at baseline. After multivariate analysis, patients with the "protective" variant indeed had an increased risk of hepatic decompensation [aHR 2.37 (1.09-5.06); p = 0.029] and liver-related mortality [aHR 2.32 (1.20-4.46); p = 0.012]. Specifically, these patients had an increased risk of developing ascites (Log-R 11.6; p < 0.001), hepatic encephalopathy (Log-R 10.2; p < 0.01), and higher mortality (Log-R 14.1; p < 0.001) at 5 years of follow-up. Interactions with the etiology of the cirrhosis and with the variant rs738409 in PNPLA3 are also described. These findings suggest that the variant rs72613567:TA in HSD17B13 has no protective effect, but indeed increases the risk of decompensation and death in patients with advanced chronic liver disease.